Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:936438.
doi: 10.1155/2011/936438. Epub 2011 Aug 22.

Nanocarriers for nitric oxide delivery

Affiliations

Nanocarriers for nitric oxide delivery

Juliana Saraiva et al. J Drug Deliv. 2011.

Abstract

Nitric oxide (NO) is a promising pharmaceutical agent that has vasodilative, antibacterial, and tumoricidal effects. To study the complex and wide-ranging roles of NO and to facilitate its therapeutic use, a great number of synthetic compounds (e.g., nitrosothiols, nitrosohydroxyamines, N-diazeniumdiolates, and nitrosyl metal complexes) have been developed to chemically stabilize and release NO in a controlled manner. Although NO is currently being exploited in many biomedical applications, its use is limited by several factors, including a short half-life, instability during storage, and potential toxicity. Additionally, efficient methods of both localized and systemic in vivo delivery and dose control are needed. One strategy for addressing these limitations and thus increasing the utility of NO donors is based on nanotechnology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scanning electron micrograph of polymeric nanoparticles containing the NO donor agent trans-[RuCl([15]ane)(NO)]2+. (a) Panoramic view. (b) Isolated magnified particle. Reprinted from Oliveira et al. [6], with the permission of Editorial Executive, Research Trends.
Figure 2
Figure 2
Generation-4 PAMAM with a completely modified exterior (64 thiols) of S-nitroso-N-acetyl-D,L-penicillamine (G4-SNAP) or S-nitroso-N-acetylcysteine (G4-NACysNO). Reprinted from Stasko et al. [76], with the permission of American Chemical Society, ACS Publications.
Figure 3
Figure 3
Structure of a OSM-PCLA-PEG-PCLA-OSM hydrogel. Reprinted from Nguyen and Lee [77], with the permission of Copyright and Licensing Manager, Wiley-VCH Verlag GmbH & Co.
Figure 4
Figure 4
Schematic representation of the stabilization of zwitterionic diazeniumdiolate by loading liposomes. Reprinted from Tai et al. [89], with the permission of Elsevier.
Figure 5
Figure 5
Nanocontainers for NO storage. Reprinted from Ghosh et al. [116], with the permission of Elsevier.
Figure 6
Figure 6
Schematic representation of the synthesis of N-diazeniumdiolate-modified SiNPs using TEOS and N-(6-aminohexyl)aminopropyltrimethoxysilane as tetraalkoxysilane and aminoalkoxysilane precursors. Reprinted from Seabra and Durán [31], with the permission of Royal Society of Chemistry (http://www.rsc.org).
Figure 7
Figure 7
In vivo targeting and imaging using QDs. (a) Ex vivo tissue examination of QD-labeled cancer cells trapped in a mouse lung [129]. (b) Near-infrared fluorescence of water-soluble type II QDs taken up by sentinel lymph nodes [130]. (c) In vivo simultaneous imaging of multicolor QD-encoded microbeads injected into a live mouse [131]. (d) Molecular targeting and in vivo imaging of a prostate tumor in a mouse using a QD-antibody conjugate (red) [131]. Reprinted from Gao et al. [128], with the permission of Elsevier.
Figure 8
Figure 8
Size-dependent optical effects of semiconductor nanoparticles. Semiconductor nanoparticles contain size-dependent electronic and optical properties. A series of five different emission spectra of sized ZnS-capped CdSe nanoparticles called QDs is used to demonstrate this principle (colored dotted lines), in juxtaposition with the absorption spectrum (solid black line).

Similar articles

Cited by

References

    1. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochemical Pharmacology. 1986;35(20):3525–3531. - PubMed
    1. Moncada S, Rees DD, Schulz R, Palmer RM. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(6):2166–2170. - PMC - PubMed
    1. Butler AR. The biological roles of nitric oxide. Chemistry and Industry. 1995;20:828–830.
    1. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annual Review of Physiology. 1995;57:683–706. - PubMed
    1. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. Journal of Cardiovascular Pharmacology. 1999;34(6):879–886. - PubMed

LinkOut - more resources